Details for Patent: 10,076,614

Which drugs does patent 10,076,614 protect, and when does it expire?

Patent 10,076,614 protects ONZETRA XSAIL and XHANCE and is included in two NDAs.

This patent has twenty-one patent family members in seventeen countries.

Summary for Patent: 10,076,614

Title:	Nasal delivery devices
Abstract:	A nasal delivery device for delivering substance to a nasal cavity of a subject comprises: a housing (15); a nosepiece (17) for fitting to a nasal cavity of the subject; a mouthpiece (19) through which the subject in use exhales; and a flexible coupling (20) which couples the mouthpiece to the housing, wherein the flexible coupling provides for asymmetric translation of the mouthpiece relative to the nosepiece.
Inventor(s):	Djupesland; Per Gisle (Oslo, NO), Gordon; Joseph (Mansfield, MA), Leclerc; Michael (Cranston, RI), Mahmoud; Ramy A (Skillman, NJ), Siwinski; Shane (Providence, RI)
Assignee:	OptiNose AS (Oslo, NO)
Application Number:	14/380,801
Patent Claim Types: see list of patent claims	Delivery; Device;

Drugs Protected by US Patent 10,076,614

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Currax	ONZETRA XSAIL	sumatriptan succinate	POWDER;NASAL	206099-001	Jan 27, 2016		RX	Yes	Yes			Y
Optinose Us Inc	XHANCE	fluticasone propionate	SPRAY, METERED;NASAL	209022-001	Sep 18, 2017		RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 10,076,614

PCT Information
PCT Filed	February 25, 2013	PCT Application Number:	PCT/EP2013/053747
PCT Publication Date:	August 29, 2013	PCT Publication Number:	WO2013/124492

International Family Members for US Patent 10,076,614

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013223973
Canada	2865353
China	104428026
Denmark	2817054
European Patent Office	2817054